Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 2:26 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 53 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Gadavist Clear all
Completed Phase 3 Interventional Results available

Gadobutrol / Gadavist-enhanced Cardiac Magnetic Resonance Imaging (CMRI) to Detect Coronary Artery Disease (CAD)

NCT01890434
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Gadobutrol (Gadavist, Gadovist, BAY86-4875)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
478 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
15
States / cities
Tucson, Arizona • Los Angeles, California • Atlanta, Georgia + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2019 · Synced Oct 19, 2026, 2:26 AM EDT
Completed Phase 2 Interventional Results available

Dose Finding Study of Gadavist in Central Nervous System (CNS) Magnetic Resonance Imaging (MRI)

NCT00862459
View directory record Official record
Conditions
Brain Diseases, Spinal Cord Diseases
Interventions
Gadobutrol~0.03 mmol/kg BW (Gadavist, Gadovist, BAY86-4875), Gadobutrol~0.1 mmol/kg BW (Gadavist, Gadovist, BAY86-4875), Gadobutrol~0.3 mmol/kg BW (Gadavist, Gadovist, BAY86-4875), OptiMARK~0.1 mmol/kg BW
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
237 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
20
States / cities
Sacramento, California • San Diego, California • Jacksonville, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2014 · Synced Oct 19, 2026, 2:26 AM EDT
Completed Phase 4 Interventional Results available

Comparison of Gadovist 75% Standard Dose to Dotarem at Full Standard Dose

NCT03602339
View directory record Official record
Conditions
Magnetic Resonance Imaging
Interventions
Gadoterate (Dotarem/Clariscan), Gadobutrol (Gadavist/Gadovist, BAY86-4875)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
4
States / cities
Chicago, Illinois • New York, New York • Hershey, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2021 · Synced Oct 19, 2026, 2:26 AM EDT
Terminated No phase listed Observational

Comparison of Contrast Agents for MRI Perfusion Analysis in Brain Tumor Patients

NCT02095353
View directory record Official record
Conditions
Central Nervous System Neoplasms
Interventions
Not listed
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Aug 23, 2023 · Synced Oct 19, 2026, 2:26 AM EDT
Withdrawn Phase 2 Interventional

PSMA-Targeted 18F-DCFPyL PET/MRI for the Detection of Prostate Cancer

NCT04910425
View directory record Official record
Conditions
Prostate Carcinoma
Interventions
Fluorine F 18 DCFPyL, Gadobenate Dimeglumine, Gadobutrol, Magnetic Resonance Imaging, Multiparametric Magnetic Resonance Imaging, Positron Emission Tomography, Transrectal Ultrasonography Guided Biopsy
Drug · Procedure
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 21, 2025 · Synced Oct 19, 2026, 2:26 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Imaging Multiple Sclerosis Lesions Using Magnevist and Gadavist

NCT01836055
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Not listed
Lead sponsor
Wayne State University
Other
Eligibility
20 Years to 59 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 9, 2014 · Synced Oct 19, 2026, 2:26 AM EDT
Completed Phase 3 Interventional Results available

Staging Prostate Cancer With Hybrid C11-Choline PET/MR and mpMRI

NCT03404648
View directory record Official record
Conditions
Prostate Adenocarcinoma
Interventions
C-11 choline PET tracer, Gadobutrol, PET/MR scanner
Drug · Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Male only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 8, 2021 · Synced Oct 19, 2026, 2:26 AM EDT
Completed Phase 4 Interventional

Dotarem vs Gadobutrol Contrast for Breast MRI

NCT03730051
View directory record Official record
Conditions
Breast Diseases
Interventions
Gadoterate meglumine, Gadobutrol
Drug
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years and older · Female only
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Oct 19, 2026, 2:26 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Gadopiclenol for Body Magnetic Resonance Imaging (MRI)

NCT03986138
View directory record Official record
Conditions
Lesion in Body Region
Interventions
gadopiclenol, Gadobutrol 1 MMOLE/ML Intravenous Solution
Drug
Lead sponsor
Guerbet
Industry
Eligibility
18 Years and older
Enrollment
324 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
7
States / cities
Birmingham, Alabama • Farmington, Connecticut • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2025 · Synced Oct 19, 2026, 2:26 AM EDT
Active, not recruiting Early Phase 1 Interventional

PET/MRI Scan for the Evaluation of Resectable Stage IA1-IB3 Cervical Cancer

NCT04219904
View directory record Official record
Conditions
Stage IA Cervical Cancer, Stage IA1 Cervical Cancer, Stage IA2 Cervical Cancer, Stage IB Cervical Cancer, Stage IB1 Cervical Cancer, Stage IB2 Cervical Cancer, Stage IB3 Cervical Cancer
Interventions
Fludeoxyglucose F-18, Gadobutrol, Magnetic Resonance Imaging, Positron Emission Tomography
Other · Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 20, 2026 · Synced Oct 19, 2026, 2:26 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Gadobutrol 1.0 Molar ( Gadavist ) in Patients for Central Nervous System (CNS) Imaging

NCT00623467
View directory record Official record
Conditions
Central Nervous System Diseases
Interventions
Gadobutrol (Gadavist, Gadovist, BAY86-4875)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
343 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
21
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 17 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2014 · Synced Oct 19, 2026, 2:26 AM EDT
Completed Phase 3 Interventional Results available

Gadobutrol Enhanced MRA of the Renal Arteries

NCT01344460
View directory record Official record
Conditions
Renal Artery Obstruction
Interventions
Gadobutrol (Gadovist, BAY86-4875)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
317 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
15
States / cities
Tucson, Arizona • Los Angeles, California • Orange, California + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2015 · Synced Oct 19, 2026, 2:26 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Coronary Atherosclerosis T1-Weighted Characterization (CATCH)

NCT03504956
View directory record Official record
Conditions
Coronary Atherosclerosis
Interventions
Cardiac MRI, Contrast, Beta blocker
Device · Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 19, 2026, 2:26 AM EDT
Withdrawn Phase 4 Interventional

Predicting Stroke Risk in ICAD With Novel MRI

NCT05515874
View directory record Official record
Conditions
Intracranial Atherosclerosis
Interventions
Feraheme
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 19, 2026, 2:26 AM EDT
Not yet recruiting Phase 1 Interventional

Dynamic Magnetic Resonance Imaging of Human Subarachnoid Space Using Intrathecal Gadolinium Contrast

NCT07796360
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Gadobutrol
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 100 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 19, 2026, 2:26 AM EDT
Completed Phase 2 Interventional Results available

Study to Find the Appropriate Dose of a New Gadolinium-based Contrast Agent (GBCA) for Adults Undergoing Magnetic Resonance Imaging (MRI) for Known or Highly Suspected Brain and/or Spinal Cord Conditions

NCT04307186
View directory record Official record
Conditions
Central Nervous System Pathology
Interventions
Gadoquatrane (BAY1747846), Gadobutrol (Gadovist/Gadavist)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
3
States / cities
Chicago, Illinois • Iowa City, Iowa • Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 15, 2023 · Synced Oct 19, 2026, 2:26 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Gadobutrol 1.0 Molar (Gadovist) for Breast Magnetic Resonance Imaging (MRI)

NCT01104584
View directory record Official record
Conditions
Breast Cancer
Interventions
Gadobutrol (Gadavist, Gadovist, BAY86-4875)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
9
States / cities
Tucson, Arizona • Oakland, California • Englewood, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 11, 2014 · Synced Oct 19, 2026, 2:26 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Gadobutrol 1.0 Molar (Gadovist) for Breast MRI

NCT01067976
View directory record Official record
Conditions
Breast Cancer, Diagnostic Imaging
Interventions
Gadobutrol (Gadavist, Gadovist, BAY86-4875)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
446 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
7
States / cities
La Jolla, California • Los Angeles, California • Newport Beach, California + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 11, 2014 · Synced Oct 19, 2026, 2:26 AM EDT
Completed No phase listed Observational

Gadolinium-Based-Contrast-Agents (GBCA) Enhancement During MR Urography

NCT03910114
View directory record Official record
Conditions
Magnetic Resonance Imaging Contrast Agents
Interventions
Magnevist, Dotarem, Gadovist
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
Up to 21 Years
Enrollment
500 participants
Timeline
1990 – 2019
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 10, 2019 · Synced Oct 19, 2026, 2:26 AM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Novel Imaging Technique to Assess Gynecologic Cancer

NCT04893434
View directory record Official record
Conditions
Gynecologic Cancer
Interventions
Gadobutrol, MRI
Drug · Diagnostic Test
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
3
States / cities
Montvale, New Jersey • New York, New York • Uniondale, New York
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Oct 19, 2026, 2:26 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Gadopiclenol for Central Nervous System (CNS) Magnetic Resonance Imaging (MRI)

NCT03996447
View directory record Official record
Conditions
CNS Lesion, Blood Brain Barrier Defect
Interventions
gadopiclenol, Gadobutrol 1Mmol/mL Solution for Injection Vial
Drug
Lead sponsor
Guerbet
Industry
Eligibility
18 Years and older
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
8
States / cities
Panorama City, California • Farmington, Connecticut • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2025 · Synced Oct 19, 2026, 2:26 AM EDT
Recruiting Phase 4 Interventional

Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years

NCT04373564
View directory record Official record
Conditions
Motor Function, Cognitive Function, Contrast Media
Interventions
Motor Tests, Cognitive Tests, Unenhanced-MRI of the brain, Gadolinium Measurements, Gadoxetate disodium, Gadobenate dimeglumine, Gadodiamide, Gadoterate meglumine, Gadobutrol, Gadoteridol
Procedure · Drug
Lead sponsor
Guerbet
Industry
Eligibility
18 Years to 64 Years
Enrollment
2,076 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
16
States / cities
Scottsdale, Arizona • New Haven, Connecticut • Chicago, Illinois + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Oct 19, 2026, 2:26 AM EDT
Recruiting Not applicable Interventional

Optimizing Contrast Dose and Scanning Parameters for Detection of Leptomeningeal Disease

NCT07415018
View directory record Official record
Conditions
Leptomeningeal Disease
Interventions
MRI Scan, VUEWAY, Gadavist
Procedure · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 18, 2026 · Synced Oct 19, 2026, 2:26 AM EDT
Completed Phase 3 Interventional Results available

Gadobutrol/Gadavist-enhanced Cardiac Magnetic Resonance Imaging (CMRI) to Detect Coronary Artery Disease (CAD)

NCT01890421
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Gadobutrol (Gadovist, Gadavist, BAY86-4875)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
426 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated May 16, 2018 · Synced Oct 19, 2026, 2:26 AM EDT